Navigation Links
Spanish gene expression data promise targeting of anti-angiogenesis treatment
Date:4/29/2010

Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs, a Spanish team reports.

Dr Eloisa Jantus from the General University Hospital of Valencia reports new findings from an analysis of 135 lung cancer specimens. She and her colleagues, led by Dr Carlos Camps, evaluated the expression of 8 different genes related to vascular endothelial growth factor (VEGF), a molecule that helps tumors develop the blood supply they need to grow larger. VEGF is a key target for new "anti-angiogenesis" drugs that aim to arrest this process.

"The vascular endothelial growth factor (VEGF) family of ligands and receptors has an important role in tumor angiogenesis," Dr Jantus said. "We studied the expression, at molecular level, of the members of this family in tumor samples as well as in normal lung tissues in order to understand their role in tumor development and prognosis."

The group measured the expression of the 8 genes, including VEGF A, -B, -C and PIGF, tyrosine-kinase receptors VEGFR-1, VEGFR-2 and VEGFR-3. In addition to these receptors, they also studied related genes for neuropilins NRP1 and NRP2.

The researchers then correlated gene expression levels with important clinical outcomes, including overall survival and the time to tumor progression, in patients whose tumors were surgically removed.

"Patients whose tumors expressed high levels of VEGF-A and VEGFR-1 tended to have a worse prognosis in terms of progression-free survival and overall survival," Dr Jantus said. "The subgroup of patients with high levels of expression of VEGF-A and VEGFR-1 showed a 30% shorter time to progression and overall survival, when compared to those with low expression levels."

The findings provide early clues that 'angiogenic profiles' could define subgroups of patients who will better benefit from the use of anti-angiogenic therapies, the researchers say.

"We think that it seems improbable that a single angiogenic marker will provide all of the relevant clinical information because only one biomarker cannot reflect the complexity of the angiogenic process; however, when the markers were considered in combination, they provided a more comprehensive pattern or profile, significantly improving their prognostic value."

These angiogenic profiles need validation in larger groups of patients before they can be implemented in the clinic, the researchers note, however they represent an emerging way to improve lung cancer therapy by tailoring it to the characteristics of individual patients and their tumors.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. LifeLinks Revolutionizes Video Interpreting, Shows Spanish Interpreting in Added Dimension-VIDEO!
2. Prescriptions Translated to Spanish Could Be Hazardous to Health
3. HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists
4. Yakult USA Launches Spanish-Language Website
5. Put Some Fiesta Into Dinner - Sam's Club Adds New Spanish Red Wine From Torres Winery
6. ECELA Spanish School in Argentina Offers Students Opportunity to Work in Buenos Aires Free Health Fair
7. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
8. Spanish-Speaking Mothers Less Likely to Turn on TV
9. Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books
10. Gene expression test reduces need for invasive heart muscle biopsy
11. Personal Tragedy Reveals Untapped Artistic Expression / Family Business Memorializes Loved Ones with Compassion During Grieving
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use ... nebulizer had a more child-friendly design, then children would be more likely to look ... to avoid the need to deliver medication via a nebulizer mask. The design will ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... LONDON , Dec. 8, 2016 KEY ... for the largest share of the market in 2016 ... This dominance can be attributed to a large number ... region. (US hold the largest share in the patient ... several benefits such as reducing loss of blood during ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
Breaking Medicine Technology: